KBC Group NV Trims Stake in Repligen Co. (NASDAQ:RGEN)

KBC Group NV lessened its position in Repligen Co. (NASDAQ:RGEN) by 25.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,215 shares of the biotechnology company’s stock after selling 754 shares during the quarter. KBC Group NV’s holdings in Repligen were worth $319,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of RGEN. UMB Bank n.a. boosted its holdings in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 110 shares during the period. First Turn Management LLC bought a new position in Repligen in the 3rd quarter valued at approximately $13,202,000. Thrivent Financial for Lutherans increased its holdings in Repligen by 6.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock worth $95,037,000 after buying an additional 36,773 shares in the last quarter. Geneva Capital Management LLC raised its stake in Repligen by 8.5% during the 3rd quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company’s stock valued at $20,638,000 after buying an additional 10,908 shares during the last quarter. Finally, TimesSquare Capital Management LLC boosted its holdings in shares of Repligen by 14.6% in the third quarter. TimesSquare Capital Management LLC now owns 275,627 shares of the biotechnology company’s stock worth $41,019,000 after buying an additional 35,115 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

RGEN has been the subject of a number of analyst reports. Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Wolfe Research began coverage on Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating on the stock. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. HC Wainwright cut their target price on Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Finally, Canaccord Genuity Group initiated coverage on shares of Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $184.73.

Repligen Price Performance

Shares of Repligen stock opened at $159.87 on Tuesday. The firm has a market cap of $8.96 billion, a PE ratio of -432.07, a P/E/G ratio of 4.67 and a beta of 0.99. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13. The business has a 50-day moving average price of $154.24 and a 200 day moving average price of $147.84. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. Repligen’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.23 EPS. Sell-side analysts predict that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.